Form 4: Aligos Therapeutics CEO Lawrence Blatt Acquires 140,103 Stock Options

Aligos Therapeutics' CEO, Lawrence Blatt, was granted 140,103 stock options on February 28, 2025, according to a Form 4 filing with the SEC.

Summary

• Lawrence Blatt, the President and CEO of Aligos Therapeutics, Inc., acquired 140,103 stock options on February 28, 2025.
• The options have an exercise price of $16.87.
• The options vest in equal monthly installments over four years, starting from February 28, 2025, and will be fully vested by February 28, 2029, contingent upon continued service.
• The expiration date for the options is February 28, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the CEO to increase shareholder value.
• Employees may see the grant as a sign of the company's commitment to its leadership.

Key Dates